Mercy Health System Corporation
Mercy Health System Corporation was paid $9.39M by Medicaid between Jan 2018 and Dec 2024, across 180 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoMERCY HEALTH SYSTEM CORPORATION
LAKE GENEVA, WI 53147
LAKE GENEVA, WI 53147
33aNPI1699728550assigned 05/19/2006
33bProvider typeOccupational Therapist
28Total paid$9.39M
24GClaims264,034
24DCodes billed180
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Occupational Therapist providers in Wisconsin
Rank by total paid#3 of 43
Median peer was paid$26K
This provider vs. median360×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MALAS, JOSEPH controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,506 | $1.25M | |
| 2019 | 36,239 | $1.08M | |
| 2020 | 33,437 | $995K | |
| 2021 | 43,631 | $1.53M | |
| 2022 | 40,632 | $1.63M | |
| 2023 | 39,538 | $1.67M | |
| 2024incomplete | 28,051 | $1.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 8,906 | 7,378 | $1.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 6,969 | 5,431 | $1.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 3,037 | 2,393 | $1.16M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6.7% | 3,321 | 1,594 | $626K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 4,369 | 3,117 | $575K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 2,505 | 1,888 | $563K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 2,943 | 2,595 | $536K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 2,541 | 1,734 | $466K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 9,109 | 6,667 | $227K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.4% | 2,825 | 2,493 | $222K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,397 | 1,259 | $112K |
| 80053 | Comprehensive metabolic panel | 1.1% | 12,619 | 10,002 | $107K |
168 more codes
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,467 | $93K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 349 | $82K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,879 | $81K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 316 | $76K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 948 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,214 | $68K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,035 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,938 | $66K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,872 | $62K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,922 | $62K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 352 | $59K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 166 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,041 | $53K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,760 | $52K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 731 | $50K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,616 | $41K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,219 | $38K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,198 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,800 | $36K |
| 73562 | <1% | 1,070 | $36K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 104 | $35K |
| 76830 | Ultrasound, transvaginal | <1% | 266 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 996 | $32K |
| 81025 | <1% | 4,054 | $31K | |
| 80061 | Lipid panel | <1% | 2,451 | $29K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,118 | $29K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 131 | $27K |
| 80050 | General health panel | <1% | 1,724 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,858 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 293 | $23K |
| 84484 | <1% | 3,647 | $22K | |
| 81001 | <1% | 8,158 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,493 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,051 | $19K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,625 | $19K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 383 | $19K |
| 85027 | <1% | 3,360 | $18K | |
| 83690 | <1% | 3,303 | $17K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 626 | $15K |
| 83735 | <1% | 3,869 | $14K | |
| 84439 | <1% | 1,485 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,123 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,990 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 49 | $11K |
| 87634 | <1% | 183 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 628 | $11K |
| 83880 | <1% | 793 | $11K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 38 | $10K |
| 96523 | <1% | 286 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 93 | $9K |
| 87186 | <1% | 1,328 | $9K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 75 | $8K |
| 87077 | <1% | 1,382 | $8K | |
| 11721 | <1% | 651 | $7K | |
| 73030 | <1% | 285 | $7K | |
| 85610 | <1% | 2,807 | $7K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,032 | $7K |
| 85730 | <1% | 2,046 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 96 | $6K |
| 82728 | <1% | 601 | $6K | |
| 36591 | <1% | 187 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,461 | $5K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 463 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,391 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 177 | $5K |
| 73610 | <1% | 219 | $4K | |
| 82962 | <1% | 2,270 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 77 | $4K |
| 0011A | <1% | 138 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,991 | $4K |
| 0012A | <1% | 131 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 218 | $4K |
| 93017 | <1% | 13 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 18 | $3K |
| 85379 | <1% | 535 | $3K | |
| 83605 | <1% | 618 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 120 | $3K |
| 84145 | <1% | 342 | $3K | |
| 84703 | <1% | 461 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 98 | $3K |
| 73630 | <1% | 136 | $2K | |
| 93975 | <1% | 14 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,893 | $2K |
| 82570 | <1% | 442 | $2K | |
| 87040 | <1% | 363 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 37 | $1K |
| 86140 | <1% | 413 | $1K | |
| 76801 | <1% | 18 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 68 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,806 | $1K |
| 73502 | <1% | 55 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,343 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,243 | $995.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,642 | $989.23 |
| 0071A | <1% | 14 | $755.16 | |
| 83550 | <1% | 108 | $742.27 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 118 | $732.08 |
| 84100 | <1% | 305 | $722.12 | |
| 84702 | <1% | 46 | $695.05 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $690.06 |
| 86850 | <1% | 187 | $600.28 | |
| 83540 | <1% | 110 | $567.95 | |
| 82043 | <1% | 103 | $560.82 | |
| 99152 | <1% | 96 | $552.31 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 27 | $459.67 |
| 82550 | <1% | 123 | $427.67 | |
| 96127 | <1% | 85 | $405.87 | |
| 86803 | <1% | 29 | $392.05 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $350.52 |
| 81003 | <1% | 151 | $349.09 | |
| 74018 | <1% | 14 | $341.14 | |
| 73130 | <1% | 16 | $336.84 | |
| 82607 | <1% | 28 | $327.60 | |
| 87581 | <1% | 15 | $310.23 | |
| 87486 | <1% | 15 | $310.23 | |
| 85651 | <1% | 91 | $300.75 | |
| 82950 | <1% | 46 | $296.34 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,822 | $291.04 |
| 85018 | <1% | 110 | $282.90 | |
| 86901 | <1% | 152 | $264.43 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 867 | $258.72 |
| 0001A | <1% | 16 | $254.10 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 145 | $252.74 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,809 | $246.58 |
| 87210 | <1% | 42 | $222.00 | |
| 85007 | <1% | 70 | $205.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,961 | $165.86 |
| 97162 | <1% | 14 | $165.06 | |
| 87070 | <1% | 26 | $146.63 | |
| 85652 | <1% | 72 | $144.99 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 42 | $123.95 |
| 82746 | <1% | 14 | $122.06 | |
| 86900 | <1% | 72 | $111.24 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 80 | $98.68 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,006 | $77.34 |
| 83615 | <1% | 15 | $56.16 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 646 | $36.30 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,697 | $25.60 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,590 | $16.27 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 403 | $15.96 |
| 96160 | <1% | 12 | $12.60 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 68 | $2.55 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 174 | $2.44 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 219 | $2.08 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 106 | $1.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,102 | $1.37 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 566 | $1.11 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 495 | $0.45 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 375 | $0.41 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 826 | $0.29 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 271 | $0.24 |
| 96376 | 0% | 258 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 144 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 115 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 75 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 15 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 19 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 41 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 48 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 25 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 237 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 142 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 411 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 493 | $0.00 |
| 90662 | 0% | 12 | $0.00 | |
| 92015 | Determination of refractive state | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALAS, JOSEPH (CFO)
Parent organizationMERCY HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Mercy Health System Corporation | Janesville, WI | $25.46M |
| Genesis Health System | Davenport, IA | $23.22M |
| Mercy Health System Corporation | Janesville, WI | $13.19M |
| Mercy Health System Corporation | Janesville, WI | $8.15M |
| Mercy Assisted Care, INC | Janesville, WI | $4.04M |
| Genesis Medical Center, Aledo | Aledo, IL | $3.62M |
| Freeport Memorial Hospital | Freeport, IL | $1.40M |
| Javon Bea Hospital | Rockford, IL | $1.23M |
| Mercy Health System Corporation | Janesville, WI | $1.17M |
| Mercy Assisted Care, INC | Harvard, IL | $601K |
| Mercyhealth Visiting Nurses Association, INC | Rockford, IL | $251K |
| Javon Bea Hospital | Rockford, IL | $174K |
| Genesis Health System | De Witt, IA | $136K |
| Mercy Assisted Care, INC | Janesville, WI | $136K |
| Genesis Health System | Bettendorf, IA | $32K |
| Mercy Assisted Care, INC | Janesville, WI | $12K |
| Mercy Harvard Hospital INC | Harvard, IL | $10K |
| Rockford Health Physicians | Rockford, IL | $9K |
| Mercy Health System Corporation | Janesville, WI | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.